Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 22, 2017
What is the competitive landscape for GALDERMA LABS LP, and when can generic versions of GALDERMA LABS LP drugs launch?
GALDERMA LABS LP has twenty-three approved drugs.| International Patents: | 376 |
| US Patents: | 60 |
| Tradenames: | 15 |
| Ingredients: | 13 |
| NDAs: | 23 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
ivermectin | Cream | 1% | SOOLANTRA | 12/30/2016 |
brimonidine | Topical Gel | 0.33% | MIRVASO | 12/15/2014 |
adapalene and benzoyl peroxide | Gel | 0.1%/2.5% | EPIDUO | 12/30/2011 |
adapalene | Topical Gel | 0.30% | DIFFERIN | 9/15/2009 |
doxycycline | Delayed-release Capsules | 40 mg | ORACEA | 12/11/2008 |
metronidazole | Topical Gel | 1% | METROGEL | 10/21/2008 |
clobetasol propionate | Spray | 0.05% | CLOBEX | 9/29/2008 |
clobetasol propionate | Topical Shampoo | 0.05% | CLOBEX | 1/9/2008 |
clobetasol propionate | Lotion | 0.05% | CLOBEX | 3/27/2006 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,624,678 | Output stage of a power amplifier having a switched-bulk biasing and adaptive biasing | ► Subscribe | |||||||||||||
| 9,258,687 | Method and system for providing tiered access to communication network resources | ► Subscribe | |||||||||||||
| 8,892,066 | Method and system for providing tiered priority access to communication network resources | ► Subscribe | |||||||||||||
| 8,729,127 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | ► Subscribe | |||||||||||||
| 5,886,038 | Composition and method for treatment of psoriasis | ► Subscribe | |||||||||||||
| 7,838,563 | Compounds, formulations, and methods for ameliorating telangiectasias | ► Subscribe | |||||||||||||
| 9,622,994 | Method for the treatment of acne using pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid | ► Subscribe | |||||||||||||
| 8,921,423 | Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid | ► Subscribe | |||||||||||||
| 8,993,571 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | ► Subscribe | |||||||||||||
| 8,275,349 | Method and system for providing tiered priority access to communication network resources | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Singapore | 189896 | ► Subscribe | |||||||||||||
| Australia | 695806 | ► Subscribe | |||||||||||||
| New Zealand | 528197 | ► Subscribe | |||||||||||||
| Portugal | 1631293 | ► Subscribe | |||||||||||||
| South Korea | 20150055082 | ► Subscribe | |||||||||||||
| Russian Federation | 2012145616 | ► Subscribe | |||||||||||||
| South Korea | 20060004667 | ► Subscribe | |||||||||||||
| Japan | 2012144554 | ► Subscribe | |||||||||||||
| Canada | 2656456 | ► Subscribe | |||||||||||||
| Argentina | 008637 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C/GB02/042 | United Kingdom | ► Subscribe | PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020418 | ||||||||||||
| 90038-5 | Sweden | ► Subscribe | PRODUCT NAME: DIMETHYL FUMARATE; REG. NO/DATE: EU/1/13/837 20140203 | ||||||||||||
| 2014000036 | Germany | ► Subscribe | PRODUCT NAME: KRISTALLINE FORM DES (R)-2-(((3-METHYL-4-(2,2,2-TRIFLUORETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAOLS; NAT. REGISTRATION NO/DATE: 87192.00.00 87193.00.00 87194.00.00 87195.00.00 20131118 FIRST REGISTRATION: SCHWEDEN 47911 47912 47913 47914 20130919 | ||||||||||||
| C/GB98/002 | United Kingdom | ► Subscribe | PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730 | ||||||||||||
| C/GB06/032 | United Kingdom | ► Subscribe | PRODUCT NAME: ENTECAVIR-(2-AMINO-1,9-DIHYDRO-9-((1S,3R,4S)-4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENE CYCLOPENTYL)-6H-PURIN-6-ONE AND HYDRATES THEREOF, PARTICULARLY THE MONOHYDRATE; REGISTERED: UK EU/1/06/343/001 20060626; UK EU/1/06/343/002 20060626; UK EU/1/06/343/003 20060626; UK EU/1/06/343/004 20060626; UK EU/1/06/343/005 20060626 | ||||||||||||
| 0812 | Netherlands | ► Subscribe | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPAANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOEZUUR, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1059 20151124 | ||||||||||||
| 0810 | Netherlands | ► Subscribe | PRODUCT NAME: SACUBITRIL/VALSARTAN, ALS HET SACUBITRIL VALSARTAN NATRIUMZOUTCOMPLEX, IE. TRINATRIURA (3-((LS,3R)-L-BIFENYL-4-YLMETHYL-3-ETHOXYCARBONYL-L-BUTYLCARBAMOYL)PROPIONAAT-(S)-3'-ETHYL-2'-(PENTANOYL(2"-(TETRAZOL-5-YLAAT)BIFENYL-4'-YLMETHYL)AMINO)BUTYRAAT) HEMIPENTAHYDRAAT; REGISTRATION NO/DATE: EU/1/15/1058 (C(2015) 8288) 20151123 | ||||||||||||
| /2015 | Austria | ► Subscribe | PRODUCT NAME: IVERMECTIN; NAT. REGISTRATION NO/DATE: 136170 20150602; FIRST REGISTRATION: MT MA 117/01101 20150402 | ||||||||||||
| 0 | Finland | ► Subscribe | |||||||||||||
| C/GB05/030 | United Kingdom | ► Subscribe | PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,983 others who get our Drug Patent Expiration Alerts:
